Joe Anderson

Joe Anderson, PhD

Chief Executive Officer

Joe has over 30 years experience in the life sciences industry with a successful track record of generating investment returns. He was a partner at Abingworth LLP for 12 years, where he led venture-capital style investments in public companies. He has founded and managed public equities funds and been a director of Algeta (acquired by Bayer AG for $2.9 billion), Amarin plc, Cytos (merged with Kuros) and Epigenomics AG, and is currently a director of Autolus Therapeutics plc, which recently listed on the Nasdaq.

Joe began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became head of the strategy team. He then moved to the City of London as a pharmaceuticals analyst at Dresdner Kleinwort Benson before being appointed as Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. Joe has a PhD in Biochemistry and extensive board level experience of building successful life science companies.

Robert Lyne

Robert Lyne

Chief Operating Officer

Robert has over 10 years' experience working with high growth technology companies. In addition to his role as Chief Operating Officer, Robert acts as the Company's General Counsel and Company Secretary.

He began his career as a lawyer at international law firm Bird & Bird LLP in London. He has advised on over 60 venture capital financings in Europe and North America as well as multiple trade exits and IPOs, working with both company boards and investors to execute complex cross-border transactions.

Robert Joined Arix in 2017 from Touchstone Innovations plc where he worked with a number of venture-backed biotechnology companies, both private and public.

Robert has a BA from the University of Oxford and an LLB from Oxford Brookes University.

James Rawlingson

James Rawlingson

Chief Financial Officer

James has over 20 years experience at board and senior management level gained across financial services, investment companies and public companies. His former roles include Group CFO of Coutts, the red carpet UK bank and wealth management division of RBS, where he held global responsibility for the finance function, and Group CFO of Charles Stanley plc, a leading UK wealth manager and fund manager.

In 1991 James joined Chase Manhattan Bank where he restructured the UK finance division following a merger with Chemical Bank. He joined UBS Investment Bank as CFO of SG Warburg & Co in 1996 where he de-authorised the UK bank ahead of a merger of UBS and SBC banks.

In 2001 James became the UK CFO of UBS Wealth Management and in 2004 moved into a global role with UBS Wealth based in Zurich. During his time at UBS he was also a director of UBS Hedge Funds Solutions Ltd.

In 2005 James joined Coutts and became global CFO whilst also serving on the boards of Coutts Finance Co, Adam & Company plc (a Scottish private bank) and was also a Non Executive Director of RBS Collective Investments Ltd where he chaired the Audit Committee.

In 2011 he moved to Charles Stanley plc, a leading wealth manager and fund manager, as Group CFO.

James qualified as a chartered accountant whilst with Deloitte and is a Chartered Member of the Chartered Institute of Securities and Investment.